First-line bevacizumab-containing therapy for HER2-negative locally advanced/metastatic breast cancer: Real-world experience from >2000 patients treated in the multicentre AVANTI study
-
Published:2021-12
Issue:
Volume:60
Page:70-77
-
ISSN:0960-9776
-
Container-title:The Breast
-
language:en
-
Short-container-title:The Breast
Author:
Müller Volkmar,
Ruhnke MarkusORCID,
Hoffmann Oliver,
Grafe AndreaORCID,
Tomé Oliver,
Fett Werner,
Bruch Harald-RobertORCID,
Sommer-Joos Ann-Katrin,
Schneeweiss Andreas
Subject
General Medicine,Surgery
Reference15 articles.
1. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer;Miller;N Engl J Med,2007
2. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer;Robert;J Clin Oncol,2011
3. TURANDOT investigators. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial;Zielinski;Lancet Oncol,2016
4. Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) – Part 2 with Recommendations for the Therapy of Primary, Recurrent and Advanced Breast Cancer
5. International consensus conference for advanced breast cancer, Lisbon 2019: ABC5 consensus - assessment by a German group of experts;Thomssen;Breast Care,2020
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献